Yin Yao1, Zhi-Chao Wang1, Di Yu2, Zheng Liu1. 1. Department of Otolaryngology-Head and Neck Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China. 2. Department of Immunology and Infectious Disease, John Curtin School of Medical Research, Australian National University, Canberra, Australia.
Abstract
PURPOSE OF REVIEW: The discovery of novel T-cell subsets including follicular helper T (Tfh) cells has broadened our knowledge on the complex immune networks in allergic diseases. This review summarizes the evidence for Tfh cells in controlling immune responses to allergens with a particular focus on immunoglobulin E (IgE) production and discusses the implication of such regulation in allergen-specific immunotherapy. RECENT FINDINGS: Tfh cells support the production of IgE in animal models for allergic diseases. Among Tfh cells, the type 2 subset (Tfh2) is considered as the major player that secretes IL-4 and promotes the isotype switching to IgE. In human inflammatory airway diseases, including allergic rhinitis, asthma, and nasal polyps, the increased frequencies of circulating or tissue Tfh2 cells have been reported. Notably, the frequencies of Dermatophagoides pteronyssinus group 1 (Der p 1)-specific IL-4 Tfh cells in blood positively correlated with serum Der p-specific IgE levels in allergic rhinitis patients. After allergen immunotherapy (AIT), Der p 1-specific IL-4 Tfh cells declined in allergic rhinitis patients, which associated with the remission of clinical symptoms. SUMMARY: Allergen-specific IL-4 Tfh cells contribute to the production of allergen-specific IgE and correlate with clinical efficacy of AIT in allergic rhinitis patients, which suggest allergen-specific Tfh cells as a promising therapeutic target and biomarker for AIT in allergic rhinitis.
PURPOSE OF REVIEW: The discovery of novel T-cell subsets including follicular helper T (Tfh) cells has broadened our knowledge on the complex immune networks in allergic diseases. This review summarizes the evidence for Tfh cells in controlling immune responses to allergens with a particular focus on immunoglobulin E (IgE) production and discusses the implication of such regulation in allergen-specific immunotherapy. RECENT FINDINGS: Tfh cells support the production of IgE in animal models for allergic diseases. Among Tfh cells, the type 2 subset (Tfh2) is considered as the major player that secretes IL-4 and promotes the isotype switching to IgE. In human inflammatory airway diseases, including allergic rhinitis, asthma, and nasal polyps, the increased frequencies of circulating or tissue Tfh2 cells have been reported. Notably, the frequencies of Dermatophagoides pteronyssinus group 1 (Der p 1)-specific IL-4 Tfh cells in blood positively correlated with serum Der p-specific IgE levels in allergic rhinitispatients. After allergen immunotherapy (AIT), Der p 1-specific IL-4 Tfh cells declined in allergic rhinitispatients, which associated with the remission of clinical symptoms. SUMMARY: Allergen-specific IL-4 Tfh cells contribute to the production of allergen-specific IgE and correlate with clinical efficacy of AIT in allergic rhinitispatients, which suggest allergen-specific Tfh cells as a promising therapeutic target and biomarker for AIT in allergic rhinitis.
Authors: J A Tuazon; B Kilburg-Basnyat; L M Oldfield; R Wiscovitch-Russo; K Dunigan-Russell; A V Fedulov; K J Oestreich; K M Gowdy Journal: Curr Allergy Asthma Rep Date: 2022-04-08 Impact factor: 4.919
Authors: Takuma Misawa; Jeffrey A SoRelle; Jin Huk Choi; Tao Yue; Kuan-Wen Wang; William McAlpine; Jianhui Wang; Aijie Liu; Koichi Tabeta; Emre E Turer; Bret Evers; Evan Nair-Gill; Subhajit Poddar; Lijing Su; Feiya Ou; Liyang Yu; Jamie Russell; Sara Ludwig; Xiaoming Zhan; Sara Hildebrand; Xiaohong Li; Miao Tang; Anne R Murray; Eva Marie Y Moresco; Bruce Beutler Journal: Sci Immunol Date: 2020-01-24
Authors: Xiaoying Zhou; Wong Yu; Diane M Dunham; Jackson P Schuetz; Catherine A Blish; Rosemarie H DeKruyff; Kari C Nadeau Journal: J Clin Invest Date: 2022-10-17 Impact factor: 19.456